SRDX: Surmodics, Inc.
About
Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. It also develops and commercializes medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. The firm operates through the following segments: Medical Device, In Vitro Diagnostics, and Corporate. The Medical Device segment designs, develops, and manufactures vascular interventional medical devices, surface modification coating technologies, as well as drug-delivery coating technologies. The In Vitro Diagnostics segment is composed of component products and technologies for diagnostic test kits and biomedical research applications. The company was founded in June 1979 and is headquartered in Eden Prairie, MN.
Current Value
$39.151 Year Return
Current Value
$39.151 Year Return
Key Details
Market Cap
$559.12M
P/E Ratio
-48.12
1Y Stock Return
15.64%
1Y Revenue Growth
-4.91%
Dividend Yield
0.00%
Price to Book
4.7
Strategies that include SRDX
Stock's related to SRDX
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| OII | <0.01% | $2.78B | +32.07% | 0.00% |
| TM | -0.01% | $230.63B | -4.27% | 1.64% |
| TRV | -0.01% | $58.86B | +48.10% | 1.59% |
| BXC | 0.01% | $1.01B | +40.40% | 0.00% |
| MMC | 0.04% | $108.41B | +10.89% | 1.37% |
| WRB | 0.05% | $22.94B | +29.98% | 0.69% |
| GOGL | 0.07% | $2.39B | +35.11% | 8.40% |
| SPR | -0.08% | $3.72B | +23.27% | 0.00% |
| TSN | -0.10% | $21.95B | +31.14% | 3.11% |
| PPC | -0.13% | $12.38B | +100.96% | 0.00% |
| NWL | -0.15% | $3.67B | +20.00% | 3.04% |
| KLG | -0.15% | $1.48B | +45.15% | 3.71% |
| KRUS | -0.15% | $1.03B | +38.71% | 0.00% |
| AFYA | 0.18% | $1.47B | -16.48% | 0.00% |
| NOG | -0.18% | $4.10B | +9.43% | 3.97% |
| UL | 0.19% | $143.25B | +21.40% | 3.25% |
| JACK | 0.19% | $880.37M | -33.18% | 3.82% |
| STVN | 0.19% | $4.95B | -32.48% | 0.32% |
| BTSG | -0.20% | $3.25B | +43.46% | 0.00% |
| GD | 0.20% | $77.26B | +14.02% | 1.98% |
ETF's related to SRDX
News
Finnhub
10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ...
Yahoo
SurModics (SRDX) could produce exceptional returns because of its solid growth attributes.
Yahoo
SurModics (SRDX) delivered earnings and revenue surprises of 51.85% and 8.27%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Yahoo
EDEN PRAIRIE, Minn. AP) — SurModics Inc. SRDX) on Wednesday reported a loss of $3.4 million in its fiscal fourth quarter.
Yahoo
EDEN PRAIRIE, Minn., November 06, 2024--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its fourth quarter and fiscal year ended September 30, 2024.
Finnhub
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results November 6, 2024 07:00 a.m. ET EDEN PRAIRIE, Minn. - Surmodics, Inc. , a leading provider of...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.